Home > Insider Trading > Filing (0001104659-13-022694)

Filing Details

Accession Number:: 0001104659-13-022694
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2013-03-20 21:32:57
Reporting Period:: 2013-03-15

Filing Date:: 2013-03-20
Accepted Time:: 2013-03-20 21:32:57
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1396814	Pacira Pharmaceuticals Inc.	PCRX	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1267959	A Fred Middleton	400 South El Camino Real Suite 1200 San Mateo CA 94402	Yes	No	No	No
1306695	Sanderling Venture Partners Vi Co Investment Fund Lp	400 South El Camino Real Suite 1200 San Mateo CA 94402	Yes	No	No	No
1306717	Sanderling Venture Partners Vi Lp	400 South El Camino Real Suite 1200 San Mateo CA 94402	Yes	No	No	No
1429282	Partnership Limited Vi Sanderling	400 South El Camino Real Suite 1200 San Mateo CA 94402	Yes	No	No	No
1429283	Sanderling Vi Beteiligungs Gmbh & Co Kg	400 South El Camino Real Suite 1200 San Mateo CA 94402	Yes	No	No	No
1429588	Vi Management Ventures Sanderling	400 South El Camino Real Suite 1200 San Mateo CA 94402	Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2013-03-15	200,000	$0.00	0	No	4	J	Direct
Common Stock	Acquisiton	2013-03-15	25,133	$0.00	67,966	No	4	J	Direct
Common Stock	Disposition	2013-03-18	28,956	$29.20	530,497	No	4	S	Direct
Common Stock	Disposition	2013-03-18	23,969	$29.20	24,688	No	4	S	Direct
Common Stock	Disposition	2013-03-18	28,558	$29.20	29,415	No	4	S	Direct
Common Stock	Disposition	2013-03-18	29,825	$28.19	500,672	No	4	S	Direct
Common Stock	Disposition	2013-03-18	24,688	$28.19	0	No	4	S	Direct
Common Stock	Disposition	2013-03-18	29,415	$28.19	0	No	4	S	Direct
Common Stock	Disposition	2013-03-19	38,250	$27.66	462,422	No	4	S	Direct
Common Stock	Disposition	2013-03-19	46,339	$26.95	416,083	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	J	Direct
No	4	J	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting persons on February 4, 2013.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.59 to $29.58, inclusive. The reporting person undertakes to provide to Pacira Pharmaceuticals, Inc., any security holder of Pacira Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) of this Form 4.
The securities are held directly by Sanderling Venture Partners VI, L.P.
The securities are held directly by Sanderling VI Beteiligungs GmbH & Co. KG. The address for Sanderling VI Beteiligungs GmbH & Co. KG is c/o Sanderling Ventures, 400 South El Camino Real, Suite 1200, San Mateo, CA 94402.
The securities are held directly by Sanderling VI Limited Partnership. The address for Sanderling VI Limited Partnership is c/o Sanderling Ventures, 400 South El Camino Real, Suite 1200, San Mateo, CA 94402.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.70 to 28.58, inclusive. The reporting person undertakes to provide to Pacira Pharmaceuticals, Inc., any security holder of Pacira Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (5) of this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.21 to $28.20, inclusive. The reporting person undertakes to provide to Pacira Pharmaceuticals, Inc., any security holder of Pacira Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (6) of this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.52 to $27.20, inclusive. The reporting person undertakes to provide to Pacira Pharmaceuticals, Inc., any security holder of Pacira Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (7) of this Form 4.
Fred Middleton, a member of the Board of Directors of the Issuer, is a managing director of Middleton, McNeil, Mills & Associates VI, LLC, which has the ultimate voting and investment power over shares held of record by Sanderling Venture Partners VI, L.P., Sanderling VI Beteiligungs GmbH & Co. KG, Sanderling VI Limited Partnership and Sanderling Venture Partners VI Co-Investment Fund, L.P. and he may be deemed to have voting and investment power over shares held of record by Sanderling Venture Partners VI, L.P.,
Sanderling VI Beteiligungs GmbH & Co. KG, Sanderling VI Limited Partnership and Sanderling Venture Partners VI Co-Investment Fund, L.P. Mr. Middleton is the owner of Sanderling Ventures Management VI and he may be deemed to have voting and investment power over shares held of record by Sanderling Ventures Management VI. Mr. Middleton disclaims beneficial ownership over the shares held by Sanderling Ventures and its affiliates, except to the extent of his pecuniary interest therein.
On March 15, 2013, Sanderling Venture Partners VI Co-Investment Fund, L.P. distributed an aggregate of 1,000,000 shares of the Issuer's common stock pro rata to its partners, including Sanderling Ventures Management VI, for no consideration (the "Distribution"). Sanderling Ventures Management VI subsequently distributed the securities received in the Distribution to its underlying members (the "GP Distribution").
The securities were held directly by Sanderling Ventures Management VI. The address for Sanderling Ventures Management VI is c/o Sanderling Ventures, 400 South El Camino Real, Suite 1200, San Mateo, CA 94402.
The securities are held directly by Mr. Middleton. On March 15, 2013, Mr. Middleton received 25,133 shares of the Issuer's common stock as a result of the GP Distribution. The address for Mr. Middleton is c/o Sanderling Ventures, 400 South El Camino Real, Suite 1200, San Mateo, CA 94402.